Peptide Partners LLC sold seven unapproved injectable peptide drugs online with disease-treatment claims, FDA says.
What happened
FDA reviewed the company's website, https://peptide.partners/, in July 2026 rather than visiting the site. The review found pages selling semaglutide, tirzepatide, retatrutide, elamipretide, tesamorelin, bremelanotide and bacteriostatic water, with text suggesting these products treat conditions such as diabetes, obesity, Alzheimer's, kidney disease and cancer. FDA says none of the products has an approved drug application.
What FDA found
FDA says the website text shows the products are meant to treat or prevent disease or change how the body works, which makes them drugs.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)The products are not generally recognized as safe and effective, so they are 'new drugs' and need an FDA-approved application, which none has.
Section 201(p) and 505(a) of the FD&C Act, 21 U.S.C. 321(p) and 355(a)Shipping these unapproved drugs across state lines is against the law.
Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)Selling bacteriostatic water to mix with the peptides shows the firm intends them to be injected into people, despite 'for research use only' statements.
21 CFR 201.128 (intended use)
What FDA wants
FDA wants a written response within 15 business days of receipt, sent to FDAAdvisory@fda.hhs.gov with reference number 735063 in the subject line. The response should list the steps taken to fix the violations, how the firm will keep them from recurring, and supporting documents.
Who should pay attention
- online sellers of 'research use only' peptides
- clinics and med spas that buy peptides from websites
- suppliers of bacteriostatic water and injection supplies
This is a summary. Read the original letter on fda.gov.